Byterna Therapeutics completed its angel plus round financing, exclusively invested by Efung Capital. Proceeds will accelerate Investigator Initiated Trial (IIT) clinical research on the circular mRNA (cmRNA) in vivo CAR‑T pipeline BR101. Founded in June 2023, Byterna is an AI‑driven biopharma focused on cmRNA‑based immunotherapy, leveraging circular mRNA and targeted tLNP technologies.
Transaction Overview
Item
Details
Financing Round
Angel Plus
Lead Investor
Efung Capital (exclusive)
Use of Proceeds
Accelerate IIT clinical research on cmRNA in vivo CAR‑T pipeline BR101
Company Founded
June 2023
Technology Focus
AI‑driven circular mRNA and targeted tLNP for immunotherapy
Technology Platform & Achievements
Technology
Capability
Seamless Circularization
Efficient cmRNA production with high circularization rates
AI Sequence Design
AI‑optimized sequences for stability and expression
Chemical Modification
Enhanced cmRNA stability and reduced immunogenicity
In Vivo Targeted Delivery
tLNP targeting T cells for in vivo CAR‑T generation
Circular mRNA CAR Design
Proprietary design and evaluation platform
Platform Status
Globally leading cmRNA in vivo CAR‑T development platform
Pipeline & Development
Pipeline
Stage
Indication
BR101 (cmRNA CAR‑T)
IIT clinical research
Undisclosed oncology target
Additional Pipelines
Multiple in vivo CAR‑T programs
Advanced preclinical/IND‑enabling
Core Pipeline
Advancing rapidly to clinical research
cmRNA CAR‑T platform
Market Opportunity & Strategic Implications
Market Size: Global CAR‑T market $7 billion (2025); in vivo CAR‑T segment projected to reach $5 billion by 2033 with cmRNA advantages
Technology Differentiation:In vivo CAR‑T eliminates ex vivo manufacturing; cmRNA offers stability vs. linear mRNA; tLNP targeting enables cell‑specific delivery
For Byterna: Angel plus funding validates platform; IIT data will support IND filing and potential Series A; exclusive Efung backing provides strategic guidance
For Investors: Early‑stage exposure to next‑generation CAR‑T; cmRNA platform has platform potential beyond oncology; AI‑driven design reduces development risk
Forward‑Looking Statements This brief contains forward‑looking statements regarding Byterna’s clinical development timeline, market potential, and financing plans. Actual results may differ due to clinical risks, competitive dynamics, or regulatory challenges.-Fineline Info & Tech
By Fineline Cube 